 | Up a level |
2022
Wolf, J., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Robeva, A., Le Mouhaer, S., Carbini, M., Yovine, A. and Heist, R. (2022). Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1. Ann. Oncol., 33. S. S42 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Groen, H. J. M., Tan, D. S. W., Garon, E. B., Demanse, D., Robeva, A., Yovine, A., Fairchild, L., Boran, A. D. and Heist, R. (2022). Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study. Ann. Oncol., 33 (7). S. S1003 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2015
Thomas, M., Schuler, M., Potzner, M., Szczudlo, T., Sutradhar, S., Yovine, A. and Wolf, J. (2015). Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases. Oncol. Res. Treat., 38. S. 270 - 271. BASEL: KARGER. ISSN 2296-5262
2014
Kim, D., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Geraldes, M., Boral, A. L., Yovine, A. and Shaw, A. T. (2014). Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. Int. J. Radiat. Oncol. Biol. Phys., 90. S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X